MDGL vs NVS
Madrigal Pharmaceuticals Inc (MDGL) versus NVS (NVS) — a side-by-side from cached financials, not a winner call.
Madrigal Pharmaceuticals Inc (MDGL) is a biotechnology company listed on NASDAQ.
NVS (NVS) common stock.
Latest reported MDGL revenue for 2024-12-31 was $180.1M. Net income was -$465.9M. MDGL currently screens at market cap $11.56B.
NVS does not have a complete income-statement cache yet.
MDGL currently screens at market cap $11.56B. NVS currently screens at market cap $0.
Not investment advice. Open the MDGL and NVS stock pages for the full models.
Not investment advice.